Zomedica Corp
ZOM
$0.0973 -0.21%
Exchange: AMEX | Sector: Healthcare | Industry: Drug Manufacturers Specialty Generic
Q4 2025
Published: Mar 13, 2025

Earnings Highlights

  • Revenue of $7.90M up 7.6% year-over-year
  • EPS of $-0.01 increased by 69.4% from previous year
  • Gross margin of 70.3%
  • Net income of -7.19M
  • ""While we experienced better revenue, our operational expenses grew significantly due to expanded marketing outreach and R&D initiatives. However, we believe these investments will pay off as we broaden our market presence."" - Zomedica CEO
ZOM
Zomedica Corp

Executive Summary

In Q4 2025, Zomedica Corp reported revenues of $7.895 million, a 12.83% increase quarter-over-quarter (QoQ) and a 7.61% rise year-over-year (YoY). Despite the revenue growth, the company faced persistent challenges with profitability, registering a net loss of $7.194 million. Management highlighted efforts to streamline operations and improve gross margins, which stood at 70.27%. Strategic investments in research and development remain pivotal as Zomedica seeks to expand its product offerings aimed at veterinarians, particularly in diagnostics and treatments for companion animals.

The quarter reflects a period of both challenges and opportunities as Zomedica aims to increase market share within the veterinary health sector. The management's commentary emphasized a forward-looking strategy focused on innovation and understanding the driving needs of veterinarians. As Zomedica continues to adjust its operational efficiencies, the company is positioned to capture a larger share of the growing market for pet health diagnostics and treatment solutions.

Key Performance Indicators

Revenue
Increasing
7.90M
QoQ: 12.83% | YoY: 7.61%
Gross Profit
Increasing
5.55M
70.27% margin
QoQ: 9.64% | YoY: 73.21%
Operating Income
Increasing
-8.16M
QoQ: -9.68% | YoY: 28.35%
Net Income
Increasing
-7.19M
QoQ: -7.42% | YoY: 67.89%
EPS
Increasing
-0.01
QoQ: -2.94% | YoY: 69.43%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 6.50 -0.07 +3.8% View
Q4 2025 7.90 -0.01 +7.6% View
Q3 2025 7.00 -0.01 +10.2% View
Q2 2025 6.13 -0.02 +1.8% View
Q1 2025 6.26 -0.01 +14.2% View